GlassScriptPhysician profile
Mehdi Ansarinia
NPI 1033233481
$305,707.71
in general payments reported to CMS, 2019-2025
33 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $61K · 2021: $78K · 2022: $72K · 2023: $15K · 2024: $6,745 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $4,327 · Travel and Lodging: $53.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,181.25 |
| Food and Beverage | $4,327.23 |
| Travel and Lodging | $53.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $66,315.89 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Lilly USA, LLC | $49,184.78 | 2019-2023 | Emgality, Reyvow |
| Allergan, INC. | $48,931.71 | 2019-2022 | |
| Amgen INC. | $46,318.44 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $25,242.22 | 2019-2025 | Ajovy, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $21,617.44 | 2020-2021 | |
| Impel Pharmaceuticals INC. | $16,181.33 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12,245.06 | 2022 | |
| Lundbeck LLC | $11,573.94 | 2019-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $4,275.48 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $798.47 | 2021-2025 | Ztlido |
| Intra-Sana Laboratories | $708.81 | 2024-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Zyla Life Sciences, INC. | $439.53 | 2019-2020 | |
| Assertio Therapeutics, INC. | $306.46 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $265.93 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $205.97 | 2021-2022 | |
| Pfizer INC. | $195.28 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $117.01 | 2019-2021 | |
| Tersera Therapeutics LLC | $112.58 | 2019 | |
| Almatica Pharma LLC | $111.03 | 2021-2022 | |
| Eli Lilly and Company | $92.53 | 2019 | |
| Biocodex, INC. | $84.74 | 2024 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Currax Pharmaceuticals LLC | $62.69 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $45.83 | 2024 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Janssen Biotech, INC. | $38.89 | 2025 | |
| Vertical Pharmaceuticals, LLC | $29.25 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.85 | 2019-2021 | |
| Baudax Bio INC. | $18.69 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.80 | 2021 | |
| Forte Bio-Pharma LLC | $15.17 | 2023 | Prolate, Nalocet |
| Endo Pharmaceuticals INC. | $14.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,025,300.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehdi Ansarinia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.